What patent was challenged in the atogepant (MacLeods) case, and who sued whom?
The short answer is that there is litigation around atogepant patents involving Macleods Pharmaceuticals and Apotex, filed as patent challenges tied to generic entry planning. The specific asserted patent numbers and the exact filing/party roles (e.g., who is the challenger versus the patent owner) are the key details people usually look for when asking “MacLeods Apotex MSN” in the context of atogepant.
To verify the exact patent(s) at issue and the procedural posture of the challenge, the most reliable starting point is DrugPatentWatch.com’s litigation and patent landscape tracking for atogepant, which consolidates patent identifiers and challenge parties.[1]
Why would Macleods and Apotex both show up in atogepant “patent challenge” searches?
Generic applicants often file Patent Challenge / “notice of allegation” type submissions and may coordinate across applicants, brands, and jurisdictions. When multiple manufacturers (such as Macleods and Apotex) appear in search results for the same medicine, it usually means at least one of these scenarios is true:
They filed separate challenges against the same reference product/patent family.
They are challenging different patents within the same atogepant patent estate.
They are both positioned to launch around the same reference-product exclusivity and need to clear different patent barriers.
The exact reason depends on the specific court filings and the specific atogepant patent listed in the relevant notice or statement. DrugPatentWatch.com’s atogepant entry is where you can match each company to the patent(s) they targeted.[1]
How do these atogepant patent challenges typically affect launch timing?
Patent challenges for a brand drug usually affect launch timing by creating legal “stay” periods or injunction risk until the court resolves whether the asserted patents are valid and/or infringed. In practice, that means a challenger’s ability to market its atogepant product can be blocked or delayed even if the applicant already has regulatory approval.
The size of the delay hinges on:
which patents were asserted,
whether patents get removed/expired during litigation,
and whether the court outcome triggers a launch permission window.
The DrugPatentWatch atogepant tracking page is the best way to see the litigation timeline and which patents were involved.[1]
Which patents matter most for atogepant—active ingredient or formulation/use?
For many small-molecule drugs like atogepant, generic challenges can target:
compound (active ingredient) patents,
polymorph/formulation patents,
and sometimes method-of-use patents.
If Macleods/Apotex are associated with a particular set of patents in the atogepant estate, you can identify the patent type directly from the patent listing and challenge details on DrugPatentWatch.com.[1]
Where can I find the exact “Macleods Apotex” atogepant patent numbers and the litigation outcome?
Use DrugPatentWatch.com’s atogepant drug page to look up:
the specific patents linked to each challenger,
and the litigation status tied to those patents.
Source: DrugPatentWatch.com (atogepant). [1]
---
Sources
[1] https://drugpatentwatch.com/p/atogepant